Kerry A Rogers
Ohio State University Comprehensive Cancer Center · Ohio State University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kerry A Rogers as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:19 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07734038 · Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaKerry Rogers · recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT06466122 · Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKiKerry Rogers · recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT03943342 · Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib ResistanceKerry Rogers · withdrawn · Chronic Lymphocytic Leukemia, Loss of Chromosome 17p · principal investigator
- Ph1/Ph2NCT02557516 · Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLLInnate Pharma · terminated · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT01841723 · Ibrutinib in Treating Patients With Relapsed Hairy Cell LeukemiaNational Cancer Institute (NCI) · active not recruiting · Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeted Therapies for Lymphoid MalignanciesR01CA177292 · NCI · OHIO STATE UNIVERSITY · fiscal years 2021 to 2025 · $538,241 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Shared Resource 10: Pharmacoanalytical Shared Resource (PhASR)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Mitch A Phelps · fiscal years 2014 to 2026Named on NCT01841723
- U01CA076576RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01841723
- The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials NetworkUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2015 to 2026Named on NCT01841723
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:19 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.N Engl J Med · 2018789 citationsRCR 27.0
- 224 citationsRCR 8.4
- Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.Haematologica · 202199 citationsRCR 5.4
- 97 citationsRCR 3.2
- Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.J Clin Oncol · 202091 citationsRCR 3.7
- Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.Cancer Discov · 202071 citationsRCR 2.9
- 67 citationsRCR 4.4
- 64 citationsRCR 2.2
- 64 citationsRCR 3.5
- Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.Am J Hematol · 202231 citationsRCR 2.6